Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016

Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016

May 2016 GlobalData Lymphoma2277 Pages Price :
$ 2500
Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2016" provides an overview of Non-Hodgkin Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Hodgkin Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Non-Hodgkin Lymphoma Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Non-Hodgkin Lymphoma 29
May 12, 2016: Epizyme to Present Data From the Tazemetostat Non-Hodgkin Lymphoma Program at American Society for Hematology Meeting on Lymphoma Biology 29
Apr 28, 2016: Kite Pharma Announces Presentations at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) 29
Apr 20, 2016: Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016 30
Apr 19, 2016: Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting 31
Apr 19, 2016: BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016 32
Apr 18, 2016: Epizyme Presents Data from Tazemetostat Clinical Pharmacology Studies at American Association for Cancer Research Annual Meeting 2016 33
Apr 18, 2016: Seattle Genetics Highlights Data on ADCETRIS at the American Association for Cancer Research Annual Meeting 33
Apr 18, 2016: TG Therapeutics Announces Pre-Clinical Data Presentation on TGR-1202 Demonstrating Differentiated Effects on T-Cells 34
Mar 18, 2016: Asana BioSciences, to Provide Update on ASN003, a Novel BRAF/PI3K Kinase Inhibitor, at the 14th International Congress on Targeted Anticancer Therapies 34
Mar 17, 2016: Epizyme to Present New Data in Support of Tazemetostat Clinical Development Program 35
Mar 17, 2016: TG Therapeutics Announces Pre-Clinical Data Presentation on TGR-1202 at the 2016 American Association for Cancer Research Annual Meeting 35
Mar 16, 2016: Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research 36
Mar 09, 2016: Genmab Achieves Second Milestone in Daratumumab NHL Study Under Collaboration with Janssen 36
Clinical Trial Profile Snapshots 38
Appendix 2274
Abbreviations 2274
Definitions 2274
Research Methodology 2275
Secondary Research 2275
About GlobalData 2276
Contact Us 2276
Disclaimer 2276
Source 2277

List of Tables
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Region, 2016* 6
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Non-Hodgkin Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Non-Hodgkin Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Non-Hodgkin Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Non-Hodgkin Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Non-Hodgkin Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Non-Hodgkin Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Non-Hodgkin Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 2275

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2500
$ 5000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top